Literature DB >> 12746394

Novel mutations in DLL3, a somitogenesis gene encoding a ligand for the Notch signalling pathway, cause a consistent pattern of abnormal vertebral segmentation in spondylocostal dysostosis.

P D Turnpenny1, N Whittock, J Duncan, S Dunwoodie, K Kusumi, S Ellard.   

Abstract

The spondylocostal dysostoses (SCD) are a group of disorders characterised by multiple vertebral segmentation defects and rib anomalies. SCD can either be sporadic or familial, and can be inherited in either autosomal dominant or recessive modes. We have previously shown that recessive forms of SCD can be caused by mutations in the delta-like 3 gene, DLL3. Here, we have sequenced DLL3 in a series of SCD cases and identified 12 mutations in a further 10 families. These include 10 novel mutations in exons 4-8, comprising nonsense, missense, frameshift, splicing, and in frame insertion mutations that are predicted to result in either the truncation of the mature protein in the extracellular domain, or affect highly conserved amino acid residues in the epidermal growth factor-like repeats of the protein. The affected cases represent diverse ethnic backgrounds and six come from traditionally consanguineous communities. In all affected subjects, the radiological phenotype is abnormal segmentation throughout the entire vertebral column with smooth outlines to the vertebral bodies in childhood, for which we suggest the term "pebble beach sign". This is a very consistent phenotype-genotype correlation and we suggest the designation SCD type 1 for the AR form caused by mutations in the DLL3 gene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746394      PMCID: PMC1735475          DOI: 10.1136/jmg.40.5.333

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  40 in total

1.  Identical twins with an autosomal recessive form of spondylocostal dysostosis.

Authors:  M Satar; M N Kozanoglu; E Atilla
Journal:  Clin Genet       Date:  1992-06       Impact factor: 4.438

2.  Spondylothoracic and spondylocostal dysostosis. Hereditary forms of spinal deformity.

Authors:  A P Roberts; A N Conner; J L Tolmie; J M Connor
Journal:  J Bone Joint Surg Br       Date:  1988-01

3.  [Costovertebral dysostosis and congenital heart disease. Four case-reports (author's transl)].

Authors:  C Delgoffe; J C Hoeffel; A M Worms; M C Bretagne; C Pernot; M Pierson
Journal:  Ann Pediatr (Paris)       Date:  1982-02

4.  Spondylocostal dysostosis: an example of autosomal dominant transmission in a large family.

Authors:  E Floor; R O De Jong; J P Fryns; C Smulders; J S Vles
Journal:  Clin Genet       Date:  1989-10       Impact factor: 4.438

5.  Spondylo-costal dysplasia. A further report--review of 14 cases.

Authors:  K Kozlowski
Journal:  Rofo       Date:  1984-02

6.  Hereditary costovertebral dysplasia with malignant cerebral tumour.

Authors:  T J David; A Glass
Journal:  J Med Genet       Date:  1983-12       Impact factor: 6.318

7.  Congenital spinal deformity in a three generation family.

Authors:  I K Temple; T G Thomas; M Baraitser
Journal:  J Med Genet       Date:  1988-12       Impact factor: 6.318

8.  Spondylocostal dysostosis: dominant type.

Authors:  P Lorenz; E Rupprecht
Journal:  Am J Med Genet       Date:  1990-02

9.  Severe spondylocostal dysostosis associated with other congenital anomalies: a clinical/epidemiologic analysis and description of ten cases from the Spanish registry.

Authors:  M L Martínez-Frías; E Bermejo; L Paisán; M Martín; J Egüés; J A López; S Martínez; C Orbea; F Cucalón; J M Gairi
Journal:  Am J Med Genet       Date:  1994-07-01

10.  Evidence for variable gene expression in a large inbred kindred with autosomal recessive spondylocostal dysostosis.

Authors:  P D Turnpenny; R J Thwaites; F N Boulos
Journal:  J Med Genet       Date:  1991-01       Impact factor: 6.318

View more
  29 in total

1.  miRNA-34c regulates Notch signaling during bone development.

Authors:  Yangjin Bae; Tao Yang; Huan-Chang Zeng; Philippe M Campeau; Yuqing Chen; Terry Bertin; Brian C Dawson; Elda Munivez; Jianning Tao; Brendan H Lee
Journal:  Hum Mol Genet       Date:  2012-04-12       Impact factor: 6.150

Review 2.  Notch and disease: a growing field.

Authors:  Angeliki Louvi; Spyros Artavanis-Tsakonas
Journal:  Semin Cell Dev Biol       Date:  2012-02-20       Impact factor: 7.727

Review 3.  Notch signaling in human development and disease.

Authors:  Andrea L Penton; Laura D Leonard; Nancy B Spinner
Journal:  Semin Cell Dev Biol       Date:  2012-01-28       Impact factor: 7.727

4.  Molecular analysis of congenital scoliosis: a candidate gene approach.

Authors:  Melissa K Maisenbacher; Ji-Soo Han; Megan L O'brien; Michael R Tracy; Bülent Erol; Alyssa A Schaffer; John P Dormans; Elaine H Zackai; Kenro Kusumi
Journal:  Hum Genet       Date:  2005-02-17       Impact factor: 4.132

Review 5.  The many facets of Notch ligands.

Authors:  B D'Souza; A Miyamoto; G Weinmaster
Journal:  Oncogene       Date:  2008-09-01       Impact factor: 9.867

6.  Clinical, genetic and environmental factors associated with congenital vertebral malformations.

Authors:  P F Giampietro; C L Raggio; R D Blank; C McCarty; U Broeckel; M A Pickart
Journal:  Mol Syndromol       Date:  2013-02

Review 7.  Notch in skeletal physiology and disease.

Authors:  E Canalis
Journal:  Osteoporos Int       Date:  2018-09-07       Impact factor: 4.507

Review 8.  Notch Signaling and the Skeleton.

Authors:  Stefano Zanotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2016-04-13       Impact factor: 19.871

9.  Tomographic assessment of the spine in children with spondylocostal dysotosis syndrome.

Authors:  Ali Al Kaissi; Klaus Klaushofer; Franz Grill
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

10.  Oncogenic role of the Notch pathway in primary liver cancer.

Authors:  Jie Lu; Yujing Xia; Kan Chen; Yuanyuan Zheng; Jianrong Wang; Wenxia Lu; Qin Yin; Fan Wang; Yingqun Zhou; Chuanyong Guo
Journal:  Oncol Lett       Date:  2016-05-18       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.